Study Showed Tarceva Improved Progression-Free Survival As A First-Line Maintenance Therapy For Advanced Non-Small Cell Lung Cancer

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a global Phase III study (SATURN) met its primary endpoint and showed Tarceva® (erlotinib) significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo.

More: continued here

Filed under: Cancer on November 11th, 2008